Led by Top Oncologist Professor Wu Yilong Expected to Commence Phase III Clinical Trial in 2H2019Demonstrates Strong R&D Capability Solidifies Oncology Drug Development Strategy
HONG KONG, CHINA - Media OutReach - 13 August 2018 - Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) ("Sihuan Pharmac...
More...






